105 related articles for article (PubMed ID: 16416673)
41. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
[TBL] [Abstract][Full Text] [Related]
42. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
Uno T; Sugimoto K; Sugawara K; Tateishi T
Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
[TBL] [Abstract][Full Text] [Related]
43. Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.
Shimatani T; Inoue M; Kuroiwa T; Moriwaki M; Xu J; Ikawa K; Morikawa N; Tazuma S
Dig Dis Sci; 2007 Feb; 52(2):390-5. PubMed ID: 17211705
[TBL] [Abstract][Full Text] [Related]
44. Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies.
Ahmad L; Iqbal Z; Shah Y; Nazir S; Khan A; Khan MI; Khan A; Khuda F; Khan I
Pak J Pharm Sci; 2018 Jul; 31(4):1363-1374. PubMed ID: 30033421
[TBL] [Abstract][Full Text] [Related]
45. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
[TBL] [Abstract][Full Text] [Related]
46. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.
Yu KS; Yim DS; Cho JY; Park SS; Park JY; Lee KH; Jang IJ; Yi SY; Bae KS; Shin SG
Clin Pharmacol Ther; 2001 Apr; 69(4):266-73. PubMed ID: 11309556
[TBL] [Abstract][Full Text] [Related]
47. Recurrent anaphylaxis linked to pantoprazole.
Kollmeier AP; Eddleston J; Zuraw BL; Christiansen SC
J Allergy Clin Immunol; 2004 Oct; 114(4):975-7. PubMed ID: 15480345
[No Abstract] [Full Text] [Related]
48. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.
Abelö A; Andersson TB; Antonsson M; Naudot AK; Skånberg I; Weidolf L
Drug Metab Dispos; 2000 Aug; 28(8):966-72. PubMed ID: 10901708
[TBL] [Abstract][Full Text] [Related]
49. Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.
Howden CW; Metz DC; Hunt B; Vakily M; Kukulka M; Amer F; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):975-84. PubMed ID: 16573800
[TBL] [Abstract][Full Text] [Related]
50. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
Sim SC; Risinger C; Dahl ML; Aklillu E; Christensen M; Bertilsson L; Ingelman-Sundberg M
Clin Pharmacol Ther; 2006 Jan; 79(1):103-13. PubMed ID: 16413245
[TBL] [Abstract][Full Text] [Related]
51. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD).
Ward RM; Tammara B; Sullivan SE; Stewart DL; Rath N; Meng X; Maguire MK; Comer GM
Eur J Clin Pharmacol; 2010 Jun; 66(6):555-61. PubMed ID: 20306184
[TBL] [Abstract][Full Text] [Related]
52. 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity.
Shu Y; Wang LS; Xu ZH; He N; Xiao WM; Wang W; Huang SL; Zhou HH
J Pharmacol Exp Ther; 2000 Nov; 295(2):844-51. PubMed ID: 11046127
[TBL] [Abstract][Full Text] [Related]
53. Correspondence between the CYP2C19 and CYP3A4 genotypes with the inferred metabolizer phenotype by omeprazole administration in Mexican healthy children.
Favela-Mendoza AF; Martínez-Cortes G; Romero-Prado MM; Romero-Tejeda EM; Islas-Carbajal MC; Sosa-Macias M; Lares-Asseff I; Rangel-Villalobos H
J Clin Pharm Ther; 2018 Oct; 43(5):656-663. PubMed ID: 29733119
[TBL] [Abstract][Full Text] [Related]
54. Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19.
Mihara K; Svensson US; Tybring G; Hai TN; Bertilsson L; Ashton M
Fundam Clin Pharmacol; 1999; 13(6):671-5. PubMed ID: 10626755
[TBL] [Abstract][Full Text] [Related]
55. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans.
Furuta T; Ohashi K; Kobayashi K; Iida I; Yoshida H; Shirai N; Takashima M; Kosuge K; Hanai H; Chiba K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 1999 Sep; 66(3):265-74. PubMed ID: 10511062
[TBL] [Abstract][Full Text] [Related]
56. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.
Chen BL; Chen Y; Tu JH; Li YL; Zhang W; Li Q; Fan L; Tan ZR; Hu DL; Wang D; Wang LS; Ouyang DS; Zhou HH
J Clin Pharmacol; 2009 May; 49(5):574-81. PubMed ID: 19398604
[TBL] [Abstract][Full Text] [Related]
57. Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction.
González HM; Romero EM; Chavez Tde J; Peregrina AA; Quezada V; Hoyo-Vadillo C
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Nov; 780(2):459-65. PubMed ID: 12401374
[TBL] [Abstract][Full Text] [Related]
58. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
59. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
[TBL] [Abstract][Full Text] [Related]
60. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19.
Bertilsson L; Tybring G; Widén J; Chang M; Tomson T
Br J Clin Pharmacol; 1997 Aug; 44(2):186-9. PubMed ID: 9278208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
